Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: An individual participant data meta-analysis of 18 HIV prevention studies
Year: 2018
Type: review
Abstract: BACKGROUND: Estimates of sexually transmitted infection (STI) prevalence are essential for efforts to prevent and control STIs. Few large STI prevalence studies exist, especially for low- and middle-income countries (LMICs). Our primary objective was to estimate the prevalence of chlamydia, gonorrhea, trichomoniasis, syphilis, herpes simplex virus type 2 (HSV-2), and bacterial vaginosis (BV) among women in sub-Saharan Africa by age, region, and population type. METHODS AND FINDINGS: We analyzed individual-level data from 18 HIV prevention studies (cohort studies and randomized controlled trials; conducted during 1993-2011), representing >37,000 women, that tested participants for ≥1 selected STIs or BV at baseline. We used a 2-stage meta-analysis to combine data. After calculating the proportion of participants with each infection and standard error by study, we used a random-effects model to obtain a summary mean prevalence of each infection and 95% confidence interval (CI) across ages, regions, and population types. Despite substantial study heterogeneity for some STIs/populations, several patterns emerged. Across the three primary region/population groups (South Africa community-based, Southern/Eastern Africa community-based, and Eastern Africa higher-risk), prevalence was higher among 15-24-year-old than 25-49-year-old women for all STIs except HSV-2. In general, higher-risk populations had greater prevalence of gonorrhea and syphilis than clinic/community-based populations. For chlamydia, prevalence among 15-24-year-olds was 10.3% (95% CI: 7.4%, 14.1%; I2 = 75.7%) among women specifically recruited from higher-risk settings for HIV in Eastern Africa and was 15.1% (95% CI: 12.7%, 17.8%; I2 = 82.3%) in South African clinic/community-based populations. Among clinic/community-based populations, prevalence was generally greater in South Africa than in Southern/Eastern Africa for most STIs; for gonorrhea, prevalence among 15-24-year-olds was 4.6% (95% CI: 3.3%, 6.4%; I2 = 82.8%) in South Africa and was 1.7% (95% CI: 1.2%, 2.6%; I2 = 55.2%) in Southern/Eastern Africa. Across the three primary region/population groups, HSV-2 and BV prevalence was high among 25-49-year-olds (ranging from 70% to 83% and 33% to 44%, respectively). The main study limitation is that the data are not from random samples of the target populations. CONCLUSIONS: Combining data from 18 HIV prevention studies, our findings highlight important features of STI/BV epidemiology among sub-Saharan African women. This methodology can be used where routine STI surveillance is limited and offers a new approach to obtaining critical information on STI and BV prevalence in LMICs.
Source: PLoS Medicine
Institutions: Centers for Disease Control and Prevention, Family Health International 360, London School of Hygiene & Tropical Medicine, University of Bristol, MRC Clinical Trials Unit at UCL, University College London, Africa Health Research Institute, University of Southampton, University of KwaZulu-Natal, University of Liverpool, Mwanza Intervention Trials Unit, National Institute for Medical Research, University of Bern, World Health Organization
Language: English
Subfield: Microbiology
Field: Immunology and Microbiology
Domain: Life Sciences
Keywords: sexually transmitted infections, bacterial vaginosis, chlamydia, gonorrhea, trichomoniasis, syphilis, herpes simplex virus type 2, STI prevalence, women, sub-Saharan Africa, age differences, community-based population, South Africa, East Africa, Southern Africa, low- and middle-income countries, sexually transmitted infection surveillance
Open Access status: gold
Estimated APC paid: $6,460
Funders: World Health Organization, UNICEF, University of Washington, National Institute for Health Research Health Protection Research Unit, National Institute for Health and Care Research, University of Bristol, Public Health England, Centers for Disease Control and Prevention, Medical Research Council
OpenAlex ID: W4294661837
